Michal Yalon-Oren

625 total citations
4 papers, 235 citations indexed

About

Michal Yalon-Oren is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Michal Yalon-Oren has authored 4 papers receiving a total of 235 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 2 papers in Pathology and Forensic Medicine and 1 paper in Molecular Biology. Recurrent topics in Michal Yalon-Oren's work include CAR-T cell therapy research (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Cancer Mechanisms and Therapy (1 paper). Michal Yalon-Oren is often cited by papers focused on CAR-T cell therapy research (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Cancer Mechanisms and Therapy (1 paper). Michal Yalon-Oren collaborates with scholars based in Australia, United Kingdom and United States. Michal Yalon-Oren's co-authors include Theodore W. Laetsch, Susan L. Cohn, Catherine Vézina, Scot Ebbinghaus, Antônio Sérgio Petrilli, Julia Glade Bender, Kumudu Pathiraja, Wayne Nicholls, Scott J. Diede and Steven G. DuBois and has published in prestigious journals such as Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Michal Yalon-Oren

4 papers receiving 233 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michal Yalon-Oren Australia	3	166	75	60	51	43	4	235
Catherine Vézina Canada	7	169 1.0×	74 1.0×	63 1.1×	59 1.2×	43 1.0×	12	295
Yuki Arakawa Japan	7	67 0.4×	63 0.8×	32 0.5×	31 0.6×	19 0.4×	31	201
Masahiro Sekimizu Japan	8	89 0.5×	44 0.6×	25 0.4×	58 1.1×	131 3.0×	42	249
Lauren Saguilig United States	7	63 0.4×	44 0.6×	16 0.3×	32 0.6×	69 1.6×	14	161
R. Erttmann Germany	9	112 0.7×	21 0.3×	58 1.0×	42 0.8×	46 1.1×	16	344
Mitsuteru Hiwatari Japan	8	49 0.3×	50 0.7×	30 0.5×	137 2.7×	29 0.7×	23	251
Ricardo López Almaraz Spain	11	43 0.3×	66 0.9×	17 0.3×	51 1.0×	31 0.7×	43	267
Rabea Wagener Germany	8	37 0.2×	25 0.3×	24 0.4×	64 1.3×	66 1.5×	26	236
W. Sanger United States	8	122 0.7×	32 0.4×	18 0.3×	49 1.0×	139 3.2×	15	240
L.F. Porrata United States	5	160 1.0×	20 0.3×	168 2.8×	39 0.8×	80 1.9×	7	355

Countries citing papers authored by Michal Yalon-Oren

Since Specialization

Citations

This map shows the geographic impact of Michal Yalon-Oren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michal Yalon-Oren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michal Yalon-Oren more than expected).

Fields of papers citing papers by Michal Yalon-Oren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michal Yalon-Oren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michal Yalon-Oren. The network helps show where Michal Yalon-Oren may publish in the future.

Co-authorship network of co-authors of Michal Yalon-Oren

This figure shows the co-authorship network connecting the top 25 collaborators of Michal Yalon-Oren. A scholar is included among the top collaborators of Michal Yalon-Oren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michal Yalon-Oren. Michal Yalon-Oren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

1.

Kilburn, Lindsay, Nada Jabado, Andrea Franson, et al.. (2021). FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma.. Journal of Clinical Oncology. 39(15_suppl). TPS10056–TPS10056. 2 indexed citations

2.

Geoerger, Birgit, Hyoung Jin Kang, Michal Yalon-Oren, et al.. (2019). Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. The Lancet Oncology. 21(1). 121–133. 208 indexed citations

3.

Geoerger, Birgit, Hyoung Jin Kang, Michal Yalon-Oren, et al.. (2018). KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1–positive advanced, relapsed or refractory solid tumor or lymphoma.. Journal of Clinical Oncology. 36(15_suppl). 10525–10525. 12 indexed citations

4.

Geoerger, Birgit, Hyoung Jin Kang, Michal Yalon-Oren, et al.. (2017). Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1⁺ advanced, relapsed, or refractory solid tumor or lymphoma.. Journal of Clinical Oncology. 35(15_suppl). 10525–10525. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact